Tissue Regenix promotes new CEO from within
pharmafile | November 2, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | biotech, drugs, pharma, pharmaceutical, tissue regenix
Just over two weeks ago, Tissue Regenix announced that its long-standing CEO, Antony Odell, would be leaving the company. It moved to replace Odell speedily, promoting its non-executive director, Steve Couldwell, to the position of CEO.
Couldwell takes on the position with a fair amount of experience at the upper echelons of the pharmaceutical industry, with his previous position prior to joining Tissue Regenix was as Chief Operating Officer of Sanofi Biosurgery. He began his career in sales, working for Smith & Nephew, the producer of surgical devices and wound care products; in the company, Couldwell rose to the position of Prseident of Orthopaedics, Europe, at the FTSE 100 company.
The incoming CEO commented on his appointment: “Since being appointed to the board in 2013, I have been impressed with the great commercial potential of our dCELL platform. The recent acquisition of CellRight Technologies has increased the market potential and provided a highly complementary product range in the $1.7 billion US bone graft and substitute market. I am delighted to be appointed CEO and look forward to leading the Group through the integration of CellRight and expansion of commercial activities as we execute our commercial strategy and grow our market share throughout the US and the rest of the world.”
Tissue Regenix were originally spun out of the University of Leeds in 2006, after commercialising research that has led to products that allow tissue cells to repopulate – allowing for the regenerative medicine to potentially be used to heal wounds, repair heart valves and knee repair.
John Samuel, Chairman, Tissue Regenix: “The Board and I are delighted to welcome Steve as the Group’s new CEO. He has an exceptional track record of growing businesses and the Board firmly believes that Steve has the required skillset and experience to guide the Group along the pathway to profitability. Alongside this, Steve has an in-depth knowledge of the Group thanks to his years as a non-executive director making him an ideal candidate for this position.”
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …
